SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a reported surge in revenue and a small float, sparking excitement about a potential massive run. The community is focused on the stock's low float and are watching for news catalysts, drawing comparisons to other stocks with similar setups. Some traders are also pointing to the stock's chart patterns as a reason for optimism.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss a potential short squeeze, noting high borrowing costs and a seemingly limited float. Community members are debating the impact of insider activity and monitoring short interest data. Some investors suggest a buy-and-hold strategy, while others point to technical indicators.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending due to discussions surrounding Amazon's competitive moves in the DSP space, sparking debates about market share and potential impacts. The community is analyzing Amazon's recent offer of head-to-head testing and ADWEEK's reporting of it. Investors are closely watching Trade Desk's response and its long-term strategies in a competitive landscape.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending as investors discuss its potential undervaluation relative to its Ethereum holdings, amplified by interest from meme stock communities and the disclosed stake of an activist investor. Community talking points revolve around its asset value, potential for a short squeeze given the low float, and comparison to other Ethereum treasury plays. However, concerns persist regarding potential dilution from convertible notes and the company's cash burn.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending amid significant stock volatility, prompting the company to release a statement clarifying they are unaware of any undisclosed material changes. The community is actively discussing potential dilution, short covering, and speculating about a possible pump and dump, while some remain bullish, citing the company's unique position in the artificial heart market.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to an upcoming FDA decision on their drug Revuforj for a specific type of leukemia, with the community actively discussing the potential market impact and likelihood of approval. While some express concerns about potential side effects and a history of sell-offs post-approval, others point to the drug's efficacy and the company's strong financial position, anticipating a significant upside if approved. Community members are closely monitoring discussions around analyst price targets, short interest, and potential buyout scenarios.

Meet DragonWifBeard: The world's first AI-powered pet dragon!  More Than Just Scales: DragonWifBeard is a real-life bearded dragon revolutionizing the pet experience. He's not just any reptile – he's equipped with cutting-edge Eliza AI agent, giving him a unique personality and the ability to interact with his environment in unprecedented ways. The Future of Companionship: This groundbreaking project merges the love for pets with the limitless possibilities of AI. Witness the dawn of a new era in companionship with DragonWithBeard.

DragonWifBeard

DragonWifBeard ($DWB) is trending as the community emphasizes its potential for profit, particularly its availability on Phantom Wallet. The conversation highlights a blend of 'ancient' and 'modern' gains, with users frequently mentioning fire and wisdom as key themes. The coin's association with other Solana tokens is also part of the discussion.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA - ADR

GNTA is experiencing significant volatility, with community members actively discussing a large pre-market surge following news of a strategic partnership. The conversation includes speculation about a short squeeze, potential for further gains, and caution due to the stock's history of volatile price action and possible pump and dump schemes. Some traders are taking profits while others are holding in anticipation of after-hours movement.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva is trending as community members discuss its potential and setbacks, with some pointing to a recent FDA approval for Uzedy as a positive catalyst. Despite some positive news, negative sentiment persists regarding the stock's performance and leadership. Analysts are weighing in, with price target adjustments and discussions around the company's "Pivot to Growth" strategy.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending amid community discussion around a recent FDA investigation into allergic reactions linked to specific lots of intravenous immune globulin (IVIG) drugs, including two ADMA products; although these reactions are acknowledged as rare, the news has sparked concerns and trading volatility. Some investors view the dip as a buying opportunity, citing the company's strong fundamentals and potential for a pre-earnings run, while others express frustration with the stock's recent performance and management's silence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of +76.47% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Healthcare technology firm Aclarion Inc.'s (ACON) stock surged nearly 127% on Monday, marking its best single-day gain since going public in 2022.&nbsp;The surge followed news that Aclarion has entered into a commercial agreement with Scripps Health, bringing its Nociscan technology — a noninvasive tool that helps physicians personalize treatment for chronic lower back pain — to Scripps' network of doctors in San Diego, California.Aclarion says the deal will allow Scripps physicians to better differentiate between painful and non-painful lumbar discs using magnetic resonance spectroscopy and advanced signal processing.&nbsp;While the partnership's financial terms were not disclosed, the news generated widespread enthusiasm among retail traders, driving a dramatic surge in trading activity and online discussions.Investor chatter on Stocktwits turned sharply bullish in response to the announcement. The company's follower count on the platform jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.A Stocktwits poll found that 41% of more than 1,100 retail traders view the partnership as a "game-changer," while 32% describe it as "short-term hype, long-term unknown." The remaining see it as a "liquidity event" or too early to make a definitive judgment.Retail traders debated the deal's broader implications, with one suggesting that it could make Aclarion a potential acquisition target for major medical technology firms.&nbsp;One user speculated that a buyout by a company like Medtronic could send the stock significantly higher, while another dismissed concerns about potential dilution, predicting a run to $10–$20.<stembedurl>https://stocktwits.com/TraderMitsos/message/606583790</stembedurl><stembedurl>https://stocktwits.com/Hotoilguy/message/606598370</stembedurl>Aclarion, which has a market capitalization of just $7.7 million, remains an early-stage company that has yet to generate revenue.&nbsp;Short interest on the stock has jumped from 11.8% at the start of 2025 to 24.2% by the end of last week, according to Koyfin.Following Monday's rally, <a href="https://stocktwits.com/symbol/ACON">Aclarion shares</a> are now up over 5% year-to-date. According to Koyfin data, only two analysts currently cover Aclarion, with one rating it a 'Buy' and the other a 'Hold.'The stock was seeing heavy profit-taking in Monday's after-hours trading, falling over 14%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Is Aclarion's Tie-Up With Scripps Health A Lasting Catalyst? Most Retail Traders Think It's A 'Game-Changer'

The company's follower count on Stocktwits jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.

Equity

The company's follower count on Stocktwits jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.


Aclarion Inc. shares surged 94% on Thursday afternoon in heavy trading after the healthcare technology company executed a 1-for-335 reverse stock split.&nbsp;The move reduced its outstanding common shares from approximately 169.4 million pre-split to around 500,000 post-split.The reverse split propelled Aclarion to the top of Stocktwits’ trending tickers, with its retail following jumping 59% from Wednesday’s close.&nbsp;Bullish traders speculated the stock could climb another 45% from current levels, while some anticipated a near-tripling.<stembedurl>https://stocktwits.com/GreenReaperx/message/602177528</stembedurl><stembedurl>https://stocktwits.com/SCNC/message/602177417</stembedurl>Aclarion specializes in Magnetic Resonance Spectroscopy (MRS) and augmented intelligence algorithms to help physicians pinpoint sources of chronic low back pain through its SaaS platform, Nociscan.&nbsp;Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.&nbsp;According to a regulatory filing, Aclarion raised about $300,000 in gross proceeds before canceling the deal, which was initiated in September 2024.Despite losing&nbsp;over 71% of its value over the past three months, Aclarion’s retail following on Stocktwits has surged 50%, with message volume soaring over 6,000%.Aclarion’s stock last had a short interest of 17.4%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Aclarion’s Retail Following Jumps 60% After Reverse Stock Split As Micro-Cap Health Tech Shares Nearly Double

Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.

Analysts Offer Insights on Healthcare Companies: Aclarion, Inc. (ACON), Edwards Lifesciences (EW) and Sanofi (OtherSNYNF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aclarion, Inc. (ACON Research Report), Edwards Lifesciences (EW...

Aclarion, Inc. (NASDAQ:ACON) Sees Large Increase in Short Interest

Aclarion, Inc. (NASDAQ:ACON  Get Free Report) saw a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 159,100 shares...

Aclarion announces publication of peer-reviewed data in journal on lumbar discs

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting...

Aclarion Announces Closing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. ( Aclarion or the Company ) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...

Aclarion Announces Pricing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ( Aclarion or the Company ) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical...

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ACON
Aclarion Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ACON News

ACONAclarion Inc